Brand C M, Leadbeater L, Bellati G, Marotta F, Ideo G
Biotechnology Development, Wellcome Research Laboratories, Beckenham, Kent, England.
J Interferon Res. 1993 Apr;13(2):121-5. doi: 10.1089/jir.1993.13.121.
Three hepatitis C patients out of 15 who received recombinant interferon-alpha 2a (rIFN-alpha 2a) therapy developed high levels of neutralizing antibody coincident with clinical relapse. On analysis, antibodies in their sera were found to also produce some neutralization of lymphoblastoid IFN. Purified lymphoblastoid IFN was separated chromatographically into 10 fractions, each containing one or two IFN-alpha subtypes, and these were used individually to examine the subtype specificity of the neutralizing antibodies in the patients' sera. All three sera neutralized all the subtypes present in the 10 lymphoblastoid IFN fractions. These findings may explain why some patients who develop antibody-mediated resistance to treatment with rIFN-alpha 2 preparations are unable to respond again when treated instead with a human cell derived preparation containing many IFN-alpha subtypes.
15名接受重组干扰素α-2a（rIFN-α2a）治疗的丙型肝炎患者中有3名产生了高水平的中和抗体，且与临床复发同时出现。经分析，发现他们血清中的抗体对淋巴母细胞样干扰素也有一定程度的中和作用。通过色谱法将纯化的淋巴母细胞样干扰素分离成10个组分，每个组分含有一种或两种干扰素α亚型，然后分别用这些组分检测患者血清中中和抗体的亚型特异性。所有三份血清均能中和10个淋巴母细胞样干扰素组分中存在的所有亚型。这些发现或许可以解释为什么一些对rIFN-α2制剂产生抗体介导耐药性的患者，在改用含有多种干扰素α亚型的人细胞源制剂治疗时无法再次产生应答。
